Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

917P - Head and neck cancer patients under (chemo-)radiotherapy undergoing nutritional intervention: Results from the prospective randomized HEADNUT-trial

Date

16 Sep 2021

Session

ePoster Display

Topics

Radiation Oncology

Tumour Site

Head and Neck Cancers

Presenters

Anna Finger

Citation

Annals of Oncology (2021) 32 (suppl_5): S786-S817. 10.1016/annonc/annonc704

Authors

A.E. Finger

Author affiliations

  • Department Of Radiotherapy And Radiation Oncology, UKE - Universitätsklinikum Hamburg-Eppendorf, 20246 - Hamburg/DE

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 917P

Background

Patients with head and neck squamous cell carcinoma (HNSCC) are often malnourished before starting the primary or adjuvant radiotherapy (RT) or chemoradiotherapy (CRT). Due to therapy related adversary effects of the RT or CRT the number of malnourished patients rises to 88% during ongoing therapy. Malnutrition can have a negative influence on therapycourse and clinical outcome. There are still not enough prospective, randomized studies on the influence of nutritional status on adversary effects of (C-)RT during therapy.

Methods

From October 2018 to October 2020, the nutritional status of 61 patients with HSNCC, randomized into a control and intervention group (IG), was measured at the beginning, every 2 weeks during and at the end of therapy. The risk of malnutrition was evaluated with established malnutrition screening tools (NRS-2002, MUST, Nutriscore) and 3-day diet diaries, patients underwent clinical examinations, laboratory analyses and bioelectrical impedance analyses. In addition, the IG had individualized nutritional counseling every 2 weeks.

Results

Before therapy, the median BMI of all patients was 23.8 (14.5-37.2) kg/m2 and after therapy median BMI fell to 22.9 (16.8-33) kg/m2 (p<0.001). The baseline median fat-free mass index (FFMI) for all patients was 18.1 (14-24.7) kg/m2, which dropped to 17.8 (13.4-21.6) kg/m2 at the ending of therapy (p<0.001). Control group patients lost more weight compared to compliant intervention group participants with a BMI <22 kg/m2(p=0.0015, CI: 0.33-2.95). MUST was the only questionnaire, which showed high sensitivity (86%) and specificity (88%) at baseline in predicting malnutrition. The 2-year overall survival rate was 70% in the control group 79% in the intervention group (log-rank p=0.79). A clear impact on the overall survival rate was observed in pretherapeutic phase angle, posttherapeutic FFMI and albumin level in blood as indicators (log-rank p=0.002, p=0.008, p=0.016).

Conclusions

Malnutrition has an adverse impact on patients’ outcome undergoing (chemo-) radiotherapy. Pretherapeutic phase angle, posttherapeutic FFMI and albumin level can be considered as indicators for overall survival.

Clinical trial identification

DRKS00016862.

Editorial acknowledgement

Legal entity responsible for the study

Dr. Anastassia Löser.

Funding

Has not received any funding.

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.